Market closed

Janux Therapeutics/$JANX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Janux Therapeutics

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Ticker

$JANX
Trading on

Industry

Biotechnology

Employees

81

JANX Metrics

BasicAdvanced
$1.7B
-
-$1.28
3.22
-
$1.7B
3.22
$65.60
$26.03
862K
59.205
59.027
2.08
2.251
-8.57%
-10.09%
143.416
1.63
1.63
-34.376
30.99%
-3.08%
42.79%
-2.59%

What the Analysts think about JANX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Janux Therapeutics stock.

JANX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

JANX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $JANX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Janux Therapeutics stock?

Janux Therapeutics (JANX) has a market cap of $1.7B as of April 04, 2025.

What is the P/E ratio for Janux Therapeutics stock?

The price to earnings (P/E) ratio for Janux Therapeutics (JANX) stock is 0 as of April 04, 2025.

Does Janux Therapeutics stock pay dividends?

No, Janux Therapeutics (JANX) stock does not pay dividends to its shareholders as of April 04, 2025.

When is the next Janux Therapeutics dividend payment date?

Janux Therapeutics (JANX) stock does not pay dividends to its shareholders.

What is the beta indicator for Janux Therapeutics?

Janux Therapeutics (JANX) has a beta rating of 3.22. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.